Due to health issues, this site is no longer maintained and will be shut down shortly. |
Forward Pharma A/S is a Danish biopharmaceutical company preparing to initiate a clinical trial using FP187, a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis, or MS, patients. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$1.95 0.00 (0.00%)
As of 12/27/2022 00:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.